Enhanced External Counterpulsation in Patients With Fontan Circulation
Primary Purpose
Single-ventricle, Congenital Heart Disease
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
EECP
Sponsored by
About this trial
This is an interventional treatment trial for Single-ventricle focused on measuring Fontan
Eligibility Criteria
Inclusion Criteria:
- Individuals with Fontan physiology being seen in the Boston Children's Hospital cardiology clinic for outpatient care.
Exclusion Criteria:
- Current pregnancy
- Decompensated heart failure/pulmonary edema
- Severe aortic insufficiency
- Active tachyarrhythmias
- Frequent atrial or ventricular ectopy
- Symptomatic peripheral vascular disease
- Thrombophlebitis or history of deep vein thrombosis or stasis ulcer
- Aortic aneurysm
- Uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure>110 mmHg)
- Systolic blood pressure <90 mmHg
- Active femoral site bleeding or hematoma
Sites / Locations
- Boston Children's Hospital
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Enhanced External Counterpulsation (EECP)
Arm Description
1 hour of treatment with EECP
Outcomes
Primary Outcome Measures
Change in cardiac output
Measurement of cardiac output (pulmonary blood flow) in L/min using inert gas rebreathing method (Innocor CO device)
Total number and type of adverse events during EECP treatment
Adverse events will be collected by an investigator and documented using CTCAE criteria
Total number and type of adverse events immediately following EECP treatment
Adverse events will be collected by an investigator and documented using CTCAE criteria
Secondary Outcome Measures
Change in ventricular strain analysis
Global mid-ventricle circumferential strain (%) and global longitudinal strain (%) calculated from speckle-tracking echocardiography
Change in qualitative ventricular systolic function
Qualitative assessment of systolic function of dominant ventricle on 2-dimensional echocardiography, categorized as normal, low normal to mildly depressed, mildly depressed, mildly to moderately depressed, moderately depressed, moderately to severely depressed, severely depressed, or unable to determine.
plasma endothelin (ET-1)
This will measure endothelial function
Total nitrate/nitrite (NOx) levels
This will measure endothelial function
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04956952
Brief Title
Enhanced External Counterpulsation in Patients With Fontan Circulation
Official Title
Enhanced External Counterpulsation in Patients With Fontan Circulation
Study Type
Interventional
2. Study Status
Record Verification Date
June 2023
Overall Recruitment Status
Completed
Study Start Date
March 31, 2022 (Actual)
Primary Completion Date
May 17, 2023 (Actual)
Study Completion Date
May 17, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Boston Children's Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of the proposed study is to determine the safety of enhanced external counterpulsation (EECP), a system for compressing the blood vessels in the legs in synchrony with an individual's cardiac rhythm, in clinically well, adult Fontan patients, to document the acute hemodynamic and myocardial effects of EECP on the Fontan circulation, and to demonstrate acute changes in endothelial function after one hour of the procedure.
Detailed Description
The investigators plan to study the effects of enhanced external counterpulsation (EECP), on patients who have had Fontan surgery for treatment of complex congenital heart disease. Eligible patient volunteers will undergo a series of biophysical measurements at rest including echocardiographic assessment of ventricular function, pulmonary blood flow/cardiac output measurement using an inert gas rebreathing method (Innocor), and measurements of biomarkers of endothelial function (ET-1, NOx). Patients will then undergo 1 hour of treatment with EECP, during which additional echocardiographic assessment of ventricular function and pulmonary blood flow/cardiac output measurements will be performed at multiple levels of leg compression. Subjects will be assessed periodically for adverse effects and discomfort during the EECP treatment. At the completion of treatment, patients will be allowed 30 minutes to rest before undergoing one more echocardiographic assessment of ventricular function, pulmonary blood flow/cardiac output measurement, and measurements of biomarkers of endothelial function (ET-1, NOx). Measurements made during and after treatment will be compared to baseline measurements.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Single-ventricle, Congenital Heart Disease
Keywords
Fontan
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
23 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Enhanced External Counterpulsation (EECP)
Arm Type
Other
Arm Description
1 hour of treatment with EECP
Intervention Type
Device
Intervention Name(s)
EECP
Intervention Description
1 hour of treatment with EECP
Primary Outcome Measure Information:
Title
Change in cardiac output
Description
Measurement of cardiac output (pulmonary blood flow) in L/min using inert gas rebreathing method (Innocor CO device)
Time Frame
Immediately prior to starting EECP treatment, during each 20-minute phase of EECP treatment, and 30 minutes after EECP treatment
Title
Total number and type of adverse events during EECP treatment
Description
Adverse events will be collected by an investigator and documented using CTCAE criteria
Time Frame
During EECP treatment (duration 60 minutes)
Title
Total number and type of adverse events immediately following EECP treatment
Description
Adverse events will be collected by an investigator and documented using CTCAE criteria
Time Frame
From completion of EECP treatment until patient discharge (30 to 60 minutes)
Secondary Outcome Measure Information:
Title
Change in ventricular strain analysis
Description
Global mid-ventricle circumferential strain (%) and global longitudinal strain (%) calculated from speckle-tracking echocardiography
Time Frame
Immediately prior to starting EECP treatment, during each 20-minute phase of EECP treatment, and 30 minutes after EECP treatment
Title
Change in qualitative ventricular systolic function
Description
Qualitative assessment of systolic function of dominant ventricle on 2-dimensional echocardiography, categorized as normal, low normal to mildly depressed, mildly depressed, mildly to moderately depressed, moderately depressed, moderately to severely depressed, severely depressed, or unable to determine.
Time Frame
Immediately prior to starting EECP treatment, during each 20-minute phase of EECP treatment, and 30 minutes after EECP treatment
Title
plasma endothelin (ET-1)
Description
This will measure endothelial function
Time Frame
pre and 30 minutes post EECP treatment
Title
Total nitrate/nitrite (NOx) levels
Description
This will measure endothelial function
Time Frame
pre and 30 minutes post EECP treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Individuals with Fontan physiology being seen in the Boston Children's Hospital cardiology clinic for outpatient care.
Exclusion Criteria:
Current pregnancy
Decompensated heart failure/pulmonary edema
Severe aortic insufficiency
Active tachyarrhythmias
Frequent atrial or ventricular ectopy
Symptomatic peripheral vascular disease
Thrombophlebitis or history of deep vein thrombosis or stasis ulcer
Aortic aneurysm
Uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure>110 mmHg)
Systolic blood pressure <90 mmHg
Active femoral site bleeding or hematoma
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fred Wu, MD
Organizational Affiliation
Attending Cardiologist
Official's Role
Principal Investigator
Facility Information:
Facility Name
Boston Children's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Enhanced External Counterpulsation in Patients With Fontan Circulation
We'll reach out to this number within 24 hrs